Are Booster Doses of Hepatitis B Vaccine Necessary?
Authors: STEPHEN C. HADLER
Journal: Annals of Internal Medicine (1988)

Editorials1 March 1988Are Booster Doses of Hepatitis B Vaccine Necessary?STEPHEN C. HADLER, M.D.STEPHEN C. HADLER, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-108-3-457 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptHepatitis B vaccines have been shown to be highly effective for preventing hepatitis B for several years or more in many populations at high risk worldwide. Attention has now turned to establishing the duration of protection offered by the vaccine and the need for vaccine booster doses. In the United States, the licensed vaccine has been widely available for more than 5 years, which is the duration of reliable protection originally estimated by the vaccine's manufacturer. However, published studies have not yet shown a decline in the protection offered by the vaccine, and booster doses of vaccine have not yet...References1. . Update on hepatitis B prevention. MMWR. 1987;36:353-60. MedlineGoogle Scholar2. HOROWITZERSHLERMCKINNEYBATTIOLA MWWR. Duration of immunity after hepatitis B vaccination: efficacy of low-dose booster vaccine. Ann Intern Med. 1988;108:185-9. LinkGoogle Scholar3. HADLERFRANCISMAYNARD SDJ. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med. 1986;315:209-14. CrossrefMedlineGoogle Scholar4. TAYLORSTEVENS PC. Persistence of antibody to hepatitis B surface antigen after vaccination with hepatitis B vaccine [Abstract]. J Med Virol. 1987;21:90A. Google Scholar5. GIBASWATKINSHINDLEDIENSTAG AECJ. Long-term persistence of protective antibody after hepatitis B vaccination of healthy adults. [Abstract]. J Med Virol. 1987;21(4):90A. Google Scholar6. CARNEWELLERWAITE CIJ. Impaired responsiveness of homosexual men with HIV antibodies to plasma-derived hepatitis B vaccine. Br Med J. 1987;294:866-8. CrossrefMedlineGoogle Scholar7. HADLERJUDSONECHENBERG SFD. Effect of prior human immunodeficiency virus infection on the outcome of hepatitis B virus infection [Abstract]. J Med Virol. 1987;21(4):87A. Google Scholar8. MCLEANHILLEMANMCALEERBUYNAK AMWE. Summary of worldwide clinical experience with HB-Vax (R) (B, MSD). J Infect. 1983;7(suppl):95-104. CrossrefMedlineGoogle Scholar9. HALSEYREPPERTMARGOLISFRANCISFIELDS NEHDH. Intradermal hepatitis B vaccination in an abbreviated schedule. Vaccine. 1986;4:228-32. CrossrefMedlineGoogle Scholar10. REDFIELDINNISSCOTTCANNONBANCROFT RBRHW. Clinical evaluation of low-dose intradermally administered hepatitis B vaccine, a cost reduction strategy. JAMA. 1985;254:3203-6. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: STEPHEN C. HADLER, M.D.Affiliations: Centers for Disease Control Atlanta, Georgia PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byRevaccination against hepatitis B in late teenagers who received vaccination during infancy: Yes or no?Acute and Chronic Viral HepatitisLong-term efficacy of plasma-derived hepatitis B vaccine: a 15-year follow-up study among Chinese childrenLong-term efficacy of plasma-derived hepatitis B vaccine among Chinese children: a 12-year follow-up studyImmune responses of prematurely born infants to hepatitis B vaccinationBooster immunization of low- and non-responders after a standard three dose hepatitis B vaccine schedule—results of a post-marketing surveillanceAn evaluation of tests in routine use for the quantitation of antibody to hepatitis B surface antigenInterpretation of hepatitis B virus serology results by medical scientistsResponse to a booster dose 18 months after a low anti-HBs response (10–99 IU/l) to three doses of intradermally or intramuscularly administered recombinant hepatitis B vaccineIntradermal hepatitis B vaccination in a 300-bed primary care hospital: Experience with a recombinant vaccine in a four-dose scheduleAccelerated schedule of hepatitis B vaccination in patients with hemophiliaNine-year follow-up study of a plasma-derived hepatitis B vaccine in a rural African settingBooster doses of hepatitis B vaccine: responses to low‐dose inoculationsA 7-year follow-up of newborns vaccinated against hepatitis BHepatitis B Virus Infection Among Swedish Adults: Aspects on Seroepidemiowgy, Transmission, and Vaccine ResponseIMPACT OF HEPATITIS B VIRUS INFECTION ON WOMEN AND CHILDRENIntramuscular versus Intradermal Administration of a Recombinant Hepatitis B Vaccine: A Comparison of Response Rates and Analysis of Factors Influencing the Antibody ResponseYeast-derived hepatitis B vaccine in dental students. A three-year follow-up studyDevelopment and persistence of antibody in a high risk institutionalized population given plasma-derived hepatitis B vaccineHepatitis B Immunoprophylaxis: Developing a Cost-Effective Program in the Hospital SettingHepatitis B Immunoprophylaxis: Developing a Cost-Effective Program in the Hospital SettingVaccines of Importance in the Hospital SettingPOST-EXPOSURE PROPHYLAXIS FOR HEPATITIS BSpecial-Use Immunobiologics for Travelers 1 March 1988Volume 108, Issue 3Page: 457-458KeywordsBooster dosesHepatitis AHepatitis BHepatitis CPopulation statisticsVaccines ePublished: 1 December 2008 Issue Published: 1 March 1988 PDF downloadLoading ...